Stelara 90 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FCFB2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,584
Award facts
- Contract value 100% obligated
- $16,584.13 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $16,584.13 to DMS Pharmaceutical Group Inc. for STELARA 90 MG/ML syringes on January 5, 2026, with completion targeted for January 27, 2026. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected under a firm fixed-price contract with no set-aside designation. This delivery order represents one of numerous purchases issued to the vendor through its Indefinite Delivery Contract under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V initiative.
The underlying Pharmaceutical Prime Vendor Global Program Generation V contract, awarded to DMS Pharmaceutical Group on November 13, 2025, carries a $499,999,999 ceiling value and extends through December 31, 2036, positioning the company as a critical regional pharmaceutical supplier for Department of Defense healthcare operations. Stelara, an immunosuppressant biologic agent, exemplifies the specialized pharmaceutical products the contractor supplies to military medical facilities worldwide. The vendor's product portfolio encompasses a comprehensive range of branded and generic prescription medications, biologics, vaccines, and medical consumables, supporting the broader $30.3 billion acquisition strategy designed to ensure consistent pharmaceutical supply across the military healthcare system.
Quick answers
Who was awarded contract SPE2DR26FCFB2?
SPE2DR26FCFB2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 5, 2026.
How much is contract SPE2DR26FCFB2 worth?
The government has obligated $16,584 on SPE2DR26FCFB2.
Is contract SPE2DR26FCFB2 an order under another contract?
Yes. SPE2DR26FCFB2 is a delivery order under SPE2DR25D9130, an indefinite delivery contract.
Was contract SPE2DR26FCFB2 competed?
The extent of competition for SPE2DR26FCFB2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award